Masayuki Ushida

Medical & Biological Laboratories Co., Ltd. engages in the research, development, manufacture and sale of biological products. It operates through the Reagents and Investment segments. The Reagent segment supplies, manufactures, and sells clinical reagents and research reagents, and its related equipment and instruments. The Investment segment deals with investments on bio-related enterprises and mediates technical partnership. The company was founded on August 23, 1969 and is headquartered in Nagoya, Japan.

ReqMed Co., Ltd. engages in drug development and consulting services. Its projects include development of pentosan polysulfate which alleviate pain symptoms of osteoarthritis, and eltoprazine which are used in the diseases such as attention-deficit hyperactivity disorder, cognitive impairment associated with schizophrenia and dyskinesia associated with Parkinson disease. The firm's clients include pharmaceutical and bio-pharmaceutical companies. The company was founded by Tadashi Matsumoto on May 12, 1998 and is headquartered in Machida, Japan.

ReqMed Venture Capital (RMVC) is the investment arm and a wholly-owned subsidiary of ReqMed Co. Ltd. ReqMed is an independent business consulting firm specializing in healthcare, established in 1998 by Kyowa Hakko Kogyo (TSE: 4151), a manufacturer of pharmaceuticals, chemicals and food products. ReqMed is headquartered in Tokyo with an office in San Francisco. The group provides services to innovative drug development businesses. ReqMed stands for Required Medicine. RMVC was established in 2003 and is located in Tokyo. The firm manages specialist venture capital funds. LSVF-I, their first Life Science Venture Fund, was established in 2000. They have entered strategic alliances with Japanese contract-research organizations including CMIC and Fuji Biomedix.

Glycoscience Laboratories, Inc. operates as a holding company that engages in the research and development of medical technologies. The firm also develops glycomedicines, with a focus on finding medical applications for glycosaminoglycans. It provides medical research on proteins, nucleic acids, and carbohydrates. The firm’s business activities include drug discovery, basic cosmetics development, and health food and supplements production. The company was founded by Akira Asari on April 15, 2005 and is headquartered in Tokyo, Japan.